BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ennaid Therapeutics, Inc. Release: Accelerated Therapeutic Development of a Dengue Virus Cure


5/2/2013 10:40:36 AM

Ennaid is developing a drug that cures all four strains of Dengue Virus

Atlanta, Georgia - May 1, 2013 - Ennaid Therapeutics, Inc. is a global biotechnology company focused on the accelerated development of a drug that cures all four strains of dengue virus, the virus that causes dengue fever, dengue hemorrhagic fever and dengue shock syndrome.

“We are excited to be doing a great humanitarian work by rapidly, safely and effectively developing our lead compound into a dengue cure against each of the virus’ four strains,” said Darnisha Harrison, founder, president and chief executive officer of Ennaid.

“Dengue virus is a mosquito-borne virus that is endemic to tropical and sub tropical regions of the world. Nearly 400 million people in 125 countries contract the virus annually. We will continue to focus on achieving key corporate and development milestones as we begin preclinical trials in non-human primates this quarter.”

Joining Darnisha in Ennaid’s success is Uday Patel, who is the former vice president of regulatory affairs and quality assurance at Inhibitex, Eric Wenzel who is the former director of clinical development at Inhibitex, Jeff Basham, who serves as Ennaid’s senior business advisor and other experts in infectious diseases and biotechnology. While 2.5 billion people are at risk for dengue infection, there are currently no drugs or vaccines available to cure or prevent the virus.

About Ennaid Therapeutics, Inc.

With its focus in infectious diseases, Ennaid was birthed out of a desire to bring cures to patients by translating complex science into medicines while employing a strategic, accelerated platform to develop and commercialize such drugs. Ennaid’s goal is not to merely treat disease symptoms, but they have an explicit vision to dispel the impossible by developing and commercializing novel drugs to cure rare and seemingly incurable diseases, thus improving the health and saving the lives of people all over the world. Founded in 2012, Ennaid is located in Atlanta, GA and Baton Rouge, LA.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES